R01FD008498

Antisense oligonucleotide treatment of ataxia-telangiectasia IND#144349 IND/IDE April 19, 2024 - Abstract

A-T is a pediatric neurodegenerative condition caused by recessive mutations in ATM, a gene which encodes a critical element of the cellular DNA damage response.

Individuals with A-T suffer from gradual loss of muscle coordination due to progressive cerebellar degeneration, leading to loss of ability to swallow, read, communicate, and ambulate.

There are currently no known effective treatments for this severely debilitating condition, and it is typically fatal by young adulthood.

Here we study the safety and effectiveness of a novel genetic treatment strategy for ataxia telangiectasia (A-T).

Antisense oligonucleotides are 15-25 nucleotide snippets of synthetic RNA-like molecules that distribute broadly in the brain and spinal cord when administered via intrathecal injection.

They bind to specific genomic targets via Watson-Crick basepairing, and can be designed to change patterns of gene splicing in therapeutically useful ways.

15% of individuals with A-T have mutations that could be treatable using splice-modulating ASOs.

Here, we test the clinical therapeutic utility of atipeksen, a 22 nucleotide ASO designed to correct the impact of ATM C.7865C>T, a recurrent mutation that causes disease by creating an abnormal splice site in ATM exon 53.

Atipeksen treatment of cell lines from A-T patients bearing this mutation inhibits use of this abnormal splice site, restoring normal ATM splicing and rescuing normal gene function.

The current clinical trial is designed to test the safety and effectiveness of atipeksen in A-T individuals bearing the ATM C.7865C>T mutation.

The goal of this study is to slow A-T associated neurodegeneration, delay the progression of neurologic symptoms of A-T, and improve quality of life, using neurologic disability rating scales, brain imaging, and exploratory biomarkers as outcomes.

Results from treated patients will be compared against a control cohort of untreated A-T patients with ATM C.7865C>T.

Success will provide an empirical foundation for advancing additional precision genetic therapies for A-T and other neurodegenerative conditions.

Children's Hospital Corporation

TO ASSIST INSTITUTIONS AND ORGANIZATIONS, TO ESTABLISH, EXPAND, AND IMPROVE RESEARCH, DEMONSTRATION, EDUCATION AND INFORMATION DISSEMINATION ACTIVITIES, ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), BIOLOGICS, BLOOD AND BLOOD PRODUCTS, THERAPEUTICS, VACCINES AND ALLERGENIC PROJECTS, DRUG HAZARDS, HUMAN AND VETERINARY DRUGS, CLINICAL TRIALS ON DRUGS AND DEVICES FOR ORPHAN PRODUCTS DEVELOPMENT, NUTRITION, SANITATION AND MICROBIOLOGICAL HAZARDS, MEDICAL DEVICES AND DIAGNOSTIC PRODUCTS, RADIATION EMITTING DEVICES AND MATERIALS, FOOD SAFETY AND FOOD ADDITIVES. THESE PROGRAMS ARE SUPPORTED DIRECTLY OR INDIRECTLY BY THE FOLLOWING CENTERS AND OFFICES: CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER), CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH), CENTER FOR VETERINARY MEDICINE (CVM), CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (CFSAN), NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR), THE OFFICE OF ORPHAN PRODUCTS DEVELOPMENT (OPD), THE CENTER FOR TOBACCO PRODUCTS (CTP), AND OFFICE OF REGULATORY AFFAIRS (ORA), AND THE OFFICE OF THE COMMISSIONER (OC). SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAMS: TO STIMULATE TECHNOLOGICAL INNOVATION, TO ENCOURAGE THE ROLE OF SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION BY MINORITY AND DISADVANTAGED PERSONS IN TECHNOLOGICAL INNOVATION. FUNDING SUPPORT FOR SCIENTIFIC CONFERENCES THAT ARE RELEVANT TO THE FDA SCIENTIFIC MISSION AND PUBLIC HEALTH ARE ALSO AVAILABLE.

93.103 - Food and Drug Administration Research

FDA Office of Acquisition and Grant Services (OAGS) [HHS - FDA]

FDA Office of the Commissioner [HHS - FDA]

Massachusetts United States

State-Wide

Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (RFA-FD-25-001)

Amendment Since initial award the total obligations have increased 300% from $893,520 to $3,577,616.